logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Latest

Lates News

date
06/05/2025
Royal Bank of Canada: Maintains rating on GFL Environmental (GFL.US) from Outperform to Outperform, with target price adjusted from $53.00 to $56.00.
Latest
4 m ago
Mattel (MAT) recorded an adjusted loss of $0.03 per share in the first quarter, better than analysts' expectations of a loss of $0.10 per share. Net sales for the first quarter were $8.266 billion, exceeding analysts' expectations of $7.886 billion. The company remains committed to its goal of repurchasing $6 billion worth of stock by 2025.
4 m ago
In the first quarter, Medtronic reported an adjusted loss of $0.03 per share, while analysts had expected a loss of $0.10 per share. Net sales for the first quarter were $8.266 billion, exceeding analysts' expectations of $7.886 billion. The company has maintained its target of repurchasing $6 billion worth of stock by 2025.
5 m ago
Lattice Semiconductor reported an adjusted EPS of $0.22 in the first quarter, in line with analyst expectations. The first quarter revenue was $1.201 billion, matching analysts' expectations. The company expects second quarter revenue to be between $1.185 billion and $1.285 billion, lower than analysts' expectations of $1.237 billion.
5 m ago
Lattice Semiconductor adjusted EPS for the first quarter was $0.22, in line with analyst expectations. First quarter revenue was $1.201 billion, matching analyst predictions of $1.201 billion. Revenue for the second quarter is expected to be between $1.185 billion and $1.285 billion, with analysts predicting $1.237 billion.
5 m ago
Vertex Pharmaceuticals' adjusted EPS for the first quarter was $4.06, analysts had expected $4.29. The company's total revenue for the year is estimated to be between $1.85 billion and $1.2 billion, compared to the original forecast of $1.8 billion to $1.2 billion. Vertex Pharmaceuticals' (VRTX) stock fell 2.84% after hours.
See all latestmore
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2025 GMT EIGHT Holdings. All Rights Reserved.